v3.26.1
GOODWILL AND INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill
Our goodwill is related to the acquisitions of Medicx Health in 2023, EvinceMed in 2022, RMDY Health, Inc. in 2019 and CareSpeak Communications in 2018. Goodwill is not amortizable for financial statement purposes.

Goodwill is tested for impairment at a reporting segment level at least annually, as of December 31, or on an interim basis if an event occurs or circumstances change. The Company considered indicators of impairment, and there were no triggering events identified, no indication of impairment of the Company's goodwill and no impairment charges recorded during the three months ended March 31, 2026 or 2025.
Intangible Assets
Intangible assets included on the condensed consolidated balance sheets consist of the following:
March 31, 2026
Gross
Carrying
Amount
Accumulated
Amortization
NetWeighted
Average Life
Remaining
Patent rights$6,838 $2,412 $4,426 6.5
Technology assets9,585 3,009 6,576 6.8
Customer relationships34,923 6,172 28,751 12.4
Total intangible assets$51,346 $11,593 $39,753 
December 31, 2025
Gross
Carrying
Amount
Accumulated
Amortization
NetWeighted
Average Life
Remaining
Patent rights$6,838 $2,252 $4,586 6.8
Technology assets9,585 2,715 6,870 7.0
Customer relationships34,923 5,583 29,340 12.6
Total intangible assets$51,346 $10,550 $40,796 
The Company recorded impairment charges of $0 in the three months ended March 31, 2026 and $368 against the value of our intangible assets during the year ended December 31, 2025. In 2023, the Company licensed certain technology to a customer under a two-year agreement. Upon receiving notice that the contract would not be renewed in 2025, and as the Company no longer utilizes the underlying technology, the patents and tradenames associated with this technology were determined to be fully impaired. Accordingly, an impairment charge of $368 was recorded and included in impairment charges within the condensed consolidated statements of operations.
The Company recorded amortization expense of $1,043 and $1,067 in the three months ended March 31, 2026 and 2025, respectively. Expected future amortization expense of the intangible assets as of March 31, 2026 is as follows:
Year ended December 31,
2026 (remainder)$3,113 
20273,857 
20283,709 
20293,676 
20303,676 
Thereafter21,722 
Total$39,753